Incyte Co. (NASDAQ:INCY) Shares Purchased by Veriti Management LLC

Veriti Management LLC raised its position in shares of Incyte Co. (NASDAQ:INCYGet Rating) by 10.3% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 14,040 shares of the biopharmaceutical company’s stock after buying an additional 1,311 shares during the quarter. Veriti Management LLC’s holdings in Incyte were worth $1,115,000 at the end of the most recent quarter.

Several other institutional investors also recently made changes to their positions in INCY. Dark Forest Capital Management LP acquired a new stake in shares of Incyte during the 3rd quarter worth approximately $33,000. AlphaMark Advisors LLC bought a new position in Incyte in the 4th quarter worth approximately $35,000. Glassman Wealth Services grew its holdings in Incyte by 52.1% in the 4th quarter. Glassman Wealth Services now owns 502 shares of the biopharmaceutical company’s stock worth $37,000 after buying an additional 172 shares in the last quarter. Desjardins Global Asset Management Inc. bought a new position in Incyte in the 4th quarter worth approximately $43,000. Finally, Lindbrook Capital LLC grew its holdings in Incyte by 577.5% in the 4th quarter. Lindbrook Capital LLC now owns 603 shares of the biopharmaceutical company’s stock worth $44,000 after buying an additional 514 shares in the last quarter. Institutional investors and hedge funds own 92.78% of the company’s stock.

INCY has been the subject of a number of recent analyst reports. Morgan Stanley increased their price objective on Incyte from $73.00 to $76.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 20th. Stifel Nicolaus increased their price target on Incyte from $75.00 to $77.00 in a research note on Tuesday, May 3rd. TheStreet lowered Incyte from a “b” rating to a “c” rating in a research note on Tuesday, May 3rd. Finally, lowered Incyte from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 14th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $87.09.

In related news, EVP Barry P. Flannelly sold 43,993 shares of Incyte stock in a transaction on Friday, April 8th. The stock was sold at an average price of $83.49, for a total transaction of $3,672,975.57. Following the completion of the sale, the executive vice president now owns 65,163 shares of the company’s stock, valued at $5,440,458.87. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 15.80% of the stock is currently owned by company insiders.

Shares of Incyte stock opened at $73.75 on Thursday. The stock has a market cap of $16.34 billion, a PE ratio of 17.56, a price-to-earnings-growth ratio of 0.86 and a beta of 0.71. The business has a fifty day simple moving average of $74.97 and a 200-day simple moving average of $73.81. The company has a quick ratio of 3.67, a current ratio of 3.71 and a debt-to-equity ratio of 0.01. Incyte Co. has a 12 month low of $61.91 and a 12 month high of $88.26.

Incyte (NASDAQ:INCYGet Rating) last issued its earnings results on Tuesday, May 3rd. The biopharmaceutical company reported $0.40 EPS for the quarter, topping the consensus estimate of $0.34 by $0.06. The business had revenue of $733.20 million during the quarter, compared to analysts’ expectations of $753.54 million. Incyte had a return on equity of 12.77% and a net margin of 29.95%. Incyte’s revenue was up 21.3% compared to the same quarter last year. During the same quarter last year, the firm posted $0.50 earnings per share. Analysts expect that Incyte Co. will post 2.31 EPS for the current fiscal year.

Incyte Profile (Get Rating)

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia.

Featured Stories

Want to see what other hedge funds are holding INCY? Visit to get the latest 13F filings and insider trades for Incyte Co. (NASDAQ:INCYGet Rating).

Institutional Ownership by Quarter for Incyte (NASDAQ:INCY)

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with's FREE daily email newsletter.